Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis

Table 2 Summaries of overall and subgroup analysis

Subtype	Categories	RCTs	No. of patients	MD	95%CI	I2 (%)	P value
Total effect analysis		13	2273	0.08	0.03-0.12	76	< 0.01
Combination drug therapy		4	613	0.14	0.01-0.28	96	< 0.01
Duration time (interaction P < 0.01)	≥ 12 wk	10	2171	0.09	0.04-0.13	71	< 0.01
	< 12 wk	3	102	0.01	-0.07-0.09	9	0.33
Ethnicity (interaction P = 0.59)	Asian	6	361	0.10	-0.01-0.20	74	< 0.01
	Caucasian	7	1912	0.06	0.02-0.11	78	< 0.01
Different SU (interaction P = 0.72)	Glimepiride	6	941	0.10	0.02-0.19	78	< 0.01
	Glibenclamide	4	528	0.08	0.01-0.15	39	0.18
Age (interaction P = 0.34)	≥ 55	8	1395	0.09	0.04-0.14	65	< 0.01
	< 55	5	878	0.05	-0.02-0.11	65	0.02
BMI (interaction P = 0.57)	≥ 28	5	1895	0.07	0.03-0.11	96.2	0.03
	< 28	8	379	0.10	-0.01-0.21	88.1	< 0.01

SU: Sulfonylurea; BMI: Body mass index; MD: Mean difference; CI: Confidence interval; RCT: Randomized controlled trial.